Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17347014 | 0.90 | TP53 (0.57) | LMNAP2RX3TP53MAPTCNR2 | |
| SCHEMBL15956289 | 0.89 | LMNA (0.70) | LMNAP2RX3TP53CNR2F2RL3 | |
| SCHEMBL1549401 | 0.88 | P2RX3 (0.61) | LMNAP2RX3TP53MAPTCNR2 | |
| SCHEMBL13762896 | 0.87 | MAPT (0.69) | LMNAP2RX3TP53MAPTCNR2 | |
| SCHEMBL17338605 | 0.85 | P2RX3 (0.57) | LMNAP2RX3TP53F2RL3 | |
| SCHEMBL18589532 | 0.84 | LMNA (0.78) | LMNATP53CNR2 | |
| SCHEMBL30125450 | 0.84 | P2RX3 (0.61) | LMNAP2RX3TP53MAPT | |
| SCHEMBL16341783 | 0.82 | CNR2 (0.63) | LMNAP2RX3TP53CNR2F2RL3 | |
| SCHEMBL11895496 | 0.82 | P2RX3 (0.62) | LMNAP2RX3TP53F2RL3 | |
| SCHEMBL1548594 | 0.81 | CHRM1 (0.76) | LMNAP2RX3TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | CBR3, AGTR1, CBR1 | LMNA 565/4885P2RX3 345/4885TP53 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.